To determine whether dapagliflozin 10 mg is superior to placebo in reducing disease progression; complications; and all-cause mortality in patients hospitalized with COVID-19Timepoint: Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up; defined as at least one of the following <br/ >Respiratory decompensation requiring initiation of invasive or non-invasive mechanical ventilation or continuous positive airway pressure (CPAP) treatment; and/or initiation of veno-venous extracorporeal membrane oxygenation (ECMO) <br/ >New or worsening congestive HFa during current hospitalization <br/ >

To determine whether dapagliflozin 10 mg is superior to placebo in reducing disease progression; complications; and all-cause mortality in patients hospitalized with COVID-19Timepoint: Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up; defined as at least one of the following <br/ >Respiratory decompensation requiring initiation of invasive or non-invasive mechanical ventilation or continuous positive airway pressure (CPAP) treatment; and/or initiation of veno-venous extracorporeal membrane oxygenation (ECMO) <br/ >New or worsening congestive HFa during current hospitalization <br/ >

N/A

N/A

To determine whether dapagliflozin 10 mg is superior to placebo in reducing disease progression; complications; and all-cause mortality in patients hospitalized with COVID-19Timepoint: Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up; defined as at least one of the following <br/ >Respiratory decompensation requiring initiation of invasive or non-invasive mechanical ventilation or continuous positive airway pressure (CPAP) treatment; and/or initiation of veno-venous extracorporeal membrane oxygenation (ECMO) <br/ >New or worsening congestive HFa during current hospitalization <br/ >

To determine whether dapagliflozin 10 mg is superior to placebo in reducing disease progression; complications; and all-cause mortality in patients hospitalized with COVID-19Timepoint: Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up; defined as at least one of the following <br/ >Respiratory decompensation requiring initiation of invasive or non-invasive mechanical ventilation or continuous positive airway pressure (CPAP) treatment; and/or initiation of veno-venous extracorporeal membrane oxygenation (ECMO) <br/ >New or worsening congestive HFa during current hospitalization <br/ >